This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Evaluation
  • Claim Credit
A Patient Centered Approach to Hypophosphatemia: Diagnosis, Evaluation, and Treatment-Enduring

A Patient Centered Approach to Hypophosphatemia: Diagnosis, Evaluation, and Treatment-Enduring



Time to Complete

2 hours


June 26, 2019


June 26, 2020
Add to Queue

Maximum Credits

2.00 / AMA PRA Category 1 Credit(s)TM
2.00 / ABIM MOC Points

An important note about ABIM MOC Part II points
Successful completion of this CME activity enables eligible participants to earn up to 2.00 ABIM-Part II Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. To claim MOC points, follow these easy steps:

Step 1: Complete all 4 questions under the "ABIM Part 2 Credit Questions" section, located at the bottom of the course evaluation form. This includes 1) attesting that our partner may submit your credits to ABIM, 2) attesting that you are ABIM board certified, 3) providing your ABIM #, and 4) providing your date of birth (MM/DD).

Step 2: Our partner, Endocrine Society, will send your MOC points to your ABIM account within 6-8 weeks.

Accredited Provider

Provided by the Endocrine Society

Commercial Supporter

This activity is supported by an educational grant from Ultragenyx Pharmaceuticals.

Program Description

Hypophosphatemia is a rare condition of low serum phosphate. The underlying cause may be from acute changes in the intake or excretion of phosphate as well as chronically low serum phosphate due to lifestyle or familial etiologies such as X-linked hypophosphatemia (XLH). Regardless, hypophosphatemia leads to a myriad of symptoms including muscle weakness, fatigue, short stature, skeletal deformities, and bone pain that range is severity and can dramatically impact quality of life and outcomes. This activity discusses the signs and symptoms and challenging evaluation of potential hypophosphatemia. Faculty will discuss non-FGF23 and FGF23-mediated hypophosphatemia and focus on devising treatment plans that take etiology into consideration.

Intended Audience

This activity is intended for endocrinologists and endocrine fellows, primary care physicians, physician’s assistants, nurse practitioners and other healthcare professionals.

Educational Objectives

Upon completion of this educational activity, learners will be better able to:

  • Incorporate best practices for evaluating and diagnosing patients with hypophosphatemia in their practice.
  • Discuss pathophysiology and treatment strategies for patients with FGF-23 mediated phosphate disorders.
  • Discuss pathophysiology and treatment strategies for patients with non-FGF-23 mediated phosphate disorders.

Conflict Of Interest Disclosure Policy

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.


Anda R. Gonciulea, MD- Program Chair
Yale New Haven Northeast Medical Group
Fairfield, CT

Dr. Gonciulea reported no relevant financial relationships during the content development process for this activity.

Suzanne M. Jan De Beur, MD
Johns Hopkins University School of Medicine
Baltimore, MD

Dr. Jan De Beur discloses the following:
Advisory Board Member: Ultragenyx;
Grant Recipient: Ultragenyx, Mereo Biopharma

Peter J. Tebben, MD
Mayo Clinic Rochester
Rochester, MN

Dr. Tebben discloses the following:
Research Investigator: Ultragenyx

Michael P. Whyte, MD
Shriners Hospital for Children
Saint Louis, MO

Dr. Whyte discloses the following:
Grant Recipient: Ultragenyx;
Research Investigator: Ultragenyx

Accredited Provider Disclosure

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships: Deborah Sellmeyer, MD

The following SPC members reported relevant financial relationship (s):
Andrew Ahmann, MD: Research Support, Dexcom, Medtronic; Consultant, Dexcom, Eli Lilly & Company, Horizon CME, MannKind, Novo Nordisk, Sanofi; Speaker, Horizon CME; Principle Investigator, National Institute of Health, T1D Exchange, Trial Net

Giuseppe Barbesino, MD: Advisory Boards, Horizon Pharmaceuticals, Ipsen Pharmaceuticals; Spouse, employee of Genzyme

Joan Han, MD: Research Support, Rhythm Pharmaceuticals; Principle Investigator, Insys Therapeutics, Rhythm Pharmaceuticals

Steven T. Harris, MD: Ad hoc consultant on Advisory Boards, Eli Lilly & Company, Radius Health; Speaker, Amgen, Eli Lilly & Company, Radius Health

Jonathan Purnell, MD: Advisor, Novo Nordisk

Neda Rasouli, MD: Research Support, Novo Nordisk, Boehringer Ingelheim, Rhythm Pharmaceuticals, Elira Therapeutics; Consultant, Intarcia

Amy Rothberg, MD: Spouse, consultant of Merck

Susmeeta Sharma, MD: Speaker, Corcept

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships:
Beret Ann Casey, MD; Lorena Alarcon-Casas Wright, MD; Neena Natt, MD




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

As an accredited provider of Continuing Medical Education (CME) by the Accreditation Council for Continuing Medical Education (ACCME), the Endocrine Society is also able to provide Maintenance of Certification (MOC) points through the ABIM MOC Assessment Recognition Program. As such, the Endocrine Society ensures that activities registered by the Society for ABIM MOC recognition meet the requirements for all MOC activities as defined by the American Board of Internal Medicine (ABIM). The Endocrine Society is responsibility for submitting participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Designation Statement

The Endocrine Society designates this enduring activity for a maximum of 2.00 AMA PRA Category 1 CreditTM  and 2.00 ABIM MOC Points. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Unlabeled Use

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.


The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

Use of professional judgment
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

Drugs and dosages
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.


To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact the Endocrine Society at

Privacy Policy

The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

myCME privacy policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue